CardioFlow Update: New Strategic Groups Formed, Board Overhauled

MicroPort CardioFlow Medtech Corporation has implemented a series of changes to its Audit, Remuneration, and Nomination Committees, alongside the establishment of a new Strategy Committee and Commercialization Committee, all effective December 15, 2025. Mr. Chen Guoming, a non-executive director and chairman of the board, has been appointed to the Audit Committee, while ceasing his roles on the Remuneration and Nomination Committees. Dr. Hu Bingshan has been redesignated as chairperson of the Nomination Committee and appointed to the Remuneration Committee, stepping down from the Audit Committee. Dr. Brian Chang, also a non-executive director, joins the Nomination Committee.

The newly formed Strategy Committee, chaired by Dr. Brian Chang, comprises six members and will focus on long-term development strategies and major decisions. This committee has already concluded that integrating heart failure management will be a core strategic focus following the proposed merger of the company's structural heart and cardiac rhythm management businesses, aiming to become a leader in heart failure diagnosis and treatment.

Additionally, a Commercialization Committee has been established, consisting of five members and chaired by Mr. Chen Guoming. Its objective is to optimize the company’s commercialization system and enhance the market competitiveness of its products.